Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107198 · ClinicalTrials.gov registry record · Phase 2
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
A Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT00107198 is a Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 188 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00107198, a Phase 2 study of Ann Arbor Stage I Childhood Hodgkin Lymphoma and Ann Arbor Stage II Childhood Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- RADIATION Radiation Therapy
- DRUG Doxorubicin Hydrochloride
- DRUG Prednisone
- PROCEDURE Conventional Surgery
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
- Kaiser Permanente-Oakland - Oakland
- Children's Hospital of Orange County - Orange
- Sutter Medical Center Sacramento - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- UCSF Medical Center-Mount Zion - San Francisco
- UCSF Medical Center-Parnassus - San Francisco
- Harbor-University of California at Los Angeles Medical Center - Torrance
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
Arizona
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2006-01-02 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107198
The ClinicalTrials.gov registry entry for NCT00107198 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ann Arbor Stage I Childhood Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00107198 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00107198 about?
NCT00107198 is a clinical study titled "Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease". This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPH...
What is the current status of trial NCT00107198?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2006-01-02. Estimated completion is 2030-12-31.
What conditions does trial NCT00107198 study?
This clinical trial studies the following conditions: Ann Arbor Stage I Childhood Hodgkin Lymphoma, Ann Arbor Stage II Childhood Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma.
What interventions are being tested in trial NCT00107198?
The interventions under investigation include: Cyclophosphamide (DRUG), Radiation Therapy (RADIATION), Doxorubicin Hydrochloride (DRUG), Prednisone (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00107198?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107198 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Ann Arbor Stage I Childhood Hodgkin Lymphoma
All registered trials for this condition
Ann Arbor Stage II Childhood Hodgkin Lymphoma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.